Somite AI Secures Series A Investment Round

Summary:

1. Somite AI, a TechBio company in Boston, secured Series A funding from various investors to accelerate human cell therapy development.
2. The company plans to focus on key therapeutic programs such as beta cells for type 1 diabetes and articular cartilage for orthopedic applications.
3. Founded by Dr. Micha Breakstone and Dr. Jonathan Rosenfeld, Somite AI is developing DeltaStem, a platform to enhance human cell production.

   Article:

   Somite AI, a TechBio company based in Boston, recently announced a successful fundraising round for its innovative work in accelerating human cell therapy development. The Series A funding, led by Khosla Ventures and supported by investors like SciFi VC and the Chan Zuckerberg Initiative, will fuel the company’s efforts to advance key therapeutic programs. These programs include the development of beta cells for type 1 diabetes, articular cartilage for orthopedic applications, satellite cells for muscular diseases, and hematopoietic cells for blood disorders.

   Co-founded by Dr. Micha Breakstone and Dr. Jonathan Rosenfeld, Somite AI is at the forefront of leveraging foundation models and proprietary AI to optimize human cell production. Their DeltaStem platform integrates capsule technology to generate valuable data on cell state transitions, which in turn enhances the development of novel cell differentiation protocols. This approach not only accelerates the process but also ensures the optimization of cell production for various therapeutic applications.

   The team at Somite AI includes renowned experts such as Prof. Olivier Pourquié from Brigham and Women’s Hospital and Harvard Medical School, Prof. Allon Klein from Harvard Medical School, Prof. Jay Shendure from the University of Washington, and Prof. Cliff Tabin from Harvard Medical School. Their collective expertise and diverse backgrounds contribute to the company’s success in pushing the boundaries of human cell therapy development.

   Overall, Somite AI’s focus on advancing key therapeutic programs and further developing the capabilities of its DeltaStem platform highlights its commitment to revolutionizing human cell therapy. With a strong foundation in AI and innovative technology, the company is poised to make significant strides in the field of biotechnology and healthcare.